On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...